Moreover, intratumoral injection of recombinant lytC_22 into CRC tumours promotes anti-PD1 therapy resistance in vivo by inducing intratumoral ARG1+ and iNOS+ MDSCs, thereby causing exacerbated T cell suppression. The gene discussed is NOS2; the disease is neoplasm.